Economic evaluation of direct-acting antiviral therapy in chronic hepatitis CZiad F Gellad, Shelby D Reed, Andrew J Muir
Corresponding author name: Ziad F Gellad
Corresponding author e-mail: firstname.lastname@example.org
Citation: Antiviral Therapy 2012; 17:1189-1199
Date published online: 05 October 2012
In 2011, the protease inhibitors boceprevir and telaprevir were approved in the United States and European Union for the treatment of hepatitis C infection. While remarkably effective, the newly approved therapies are also accompanied by additional side effects and considerable costs. Understanding the balance between costs and effectiveness is critical to making decisions about the optimal use of these new agents, especially for health care systems constrained by rising costs. Our goal for this review is to facilitate an understanding of the importance of cost-effectiveness analyses in guiding policy decisions about the use of newly approved drugs as well as future therapies for hepatitis C.